General Information
Drug ID
DR00273
Drug Name
Danoprevir
Synonyms
DANOPREVIR; ITMN-191; Danoprevir (ITMN-191); Danoprevir (RG7227); UNII-911Z9PCQ5F; ITMN 191; RO5190591; 911Z9PCQ5F; R 7227; RG7227; R7227; Intermune ITMN-191; ITMN B; Danoprevir [USAN:INN]; R-7227; (2R,6S,13aS,14aR,16aS,Z)-6-((tert-butoxycarbonyl)amino)-14a-((cyclopropylsulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1; Danoprevir (ITMN191); MLS006011139; R 05190591; CHEMBL258734; C35H46FN5O9S; SCHEMBL2289034; AOB87156; ZINC29058869; s1183; RL05263
Drug Type
Small molecular drug
Indication Hepatitis C virus infection [ICD11: 1E50.2, 1E51.1] Phase 2 [1]
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=11285588"></iframe>
3D MOL 2D MOL
Formula
C35H46FN5O9S
Canonical SMILES
CC(C)(C)OC(=O)NC1CCCCCC=CC2CC2(NC(=O)C3CC(CN3C1=O)OC(=O)N4CC5=C(C4)C(=CC=C5)F)C(=O)NS(=O)(=O)C6CC6
InChI
InChI=1S/C35H46FN5O9S/c1-34(2,3)50-32(45)37-27-13-8-6-4-5-7-11-22-17-35(22,31(44)39-51(47,48)24-14-15-24)38-29(42)28-16-23(19-41(28)30(27)43)49-33(46)40-18-21-10-9-12-26(36)25(21)20-40/h7,9-12,22-24,27-28H,4-6,8,13-20H2,1-3H3,(H,37,45)(H,38,42)(H,39,44)/b11-7-/t22-,23-,27+,28+,35-/m1/s1
InChIKey
ZVTDLPBHTSMEJZ-JSZLBQEHSA-N
CAS Number
CAS 850876-88-9
Pharmaceutical Properties Molecular Weight 731.8 Topological Polar Surface Area 189
Heavy Atom Count 51 Rotatable Bond Count 8
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 10
PubChem CID
11285588
PubChem SID
135626636 , 137357790 , 164193942 , 56472168 , 81020649
TTD Drug ID
D0R9MN
DT(s) Transporting This Drug OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [2]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [2]
References
1 ClinicalTrials.gov (NCT01220947) A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
2 FDA Drug Development and Drug Interactions

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.